Page last updated: 2024-09-04

docetaxel anhydrous and Bone Neoplasms

docetaxel anhydrous has been researched along with Bone Neoplasms in 334 studies

Research

Studies (334)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (2.10)	18.2507
2000's	115 (34.43)	29.6817
2010's	178 (53.29)	24.3611
2020's	34 (10.18)	2.80

Authors

Authors	Studies
Bernstein, ML; Bomgaars, LR; Collier, AB; Dang, HM; DuBois, SG; Gorlick, RG; Hawkins, DS; Janeway, KA; Krailo, MD; Reed, DR	1
Enokida, H; Hashine, K; Ichikawa, T; Kamiyama, M; Matsuyama, H; Mizokami, A; Nakajima, K; Nishimoto, K; Shiina, H; Sugiyama, Y; Takahashi, S	1
Gao, P; Huang, J; Jiang, S; Liu, Q; Wang, H; Yao, L; Zhang, T; Zhang, X	1
Enokida, H; Harada, K; Hashine, K; Horikoshi, H; Ichikawa, T; Ito, A; Kamijima, T; Kamiyama, M; Matsuyama, H; Miyao, T; Mizokami, A; Nakajima, K; Nishimoto, K; Shiina, H; Sugiyama, Y; Takahashi, S; Yaegashi, H	1
Ishida, T; Koseki, T; Tada, H; Takahashi, N; Tanda, N; Washio, J	1
Guo, P; Lun Wong, H; Wen, W; Xue, HY	1
Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y	1
Jiang, S; Meng, Q; Wei, L; Xiong, B; Zhang, D; Zhang, S; Zhang, X	1
Abramowitz, E; O'Sullivan, JM; Sierra-Scacalossi, L	1
Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S	1
Dai, J; Escara-Wilke, J; Keller, ET; Robinson, T; Zimmermann, J	1
George, DJ	1
Bourlon, MT; Gabutti, A; Remolina-Bonilla, YA; Saldivar-Oviedo, B; Trejo-Rosales, RR	1
Elabbady, A; Elsaqa, M; Sharafeldeen, M	1
Gao, Y; Labhasetwar, V; Midura, RJ; Rahman, MT; Rozic, R; Sharifi, N; Vijayaraghavalu, S	1
Aggarwal, R; Bok, RA; Carvajal, L; Chen, HY; Gordon, JW; Kurhanewicz, J; Larson, PEZ; Lee, P; Ohliger, MA; Slater, JB; Small, EJ; van Criekinge, M; Vigneron, DB; Zhu, Z	1
Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F	1
Al-Adhami, M; Armstrong, AJ; Beer, TM; de Bono, J; Lin, P; Parli, T; Scher, HI; Steinberg, J; Sternberg, CN; Sugg, J; Tombal, B	1
Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W	1
Colapietro, A; Del Fattore, A; Delle Monache, S; Festuccia, C; Fogler, W; Gravina, GL; Iorio, R; Magnani, J; Mancini, A; Pompili, S; Ventura, L; Vetuschi, A	1
Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E	1
Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G	1
Bai, SB; Cheng, Y; Ji, QF; Liu, DZ; Liu, M; Mei, QB; Zhang, BL; Zhou, SY	1
Allen, RJ; Bishop, RT; Capulli, M; Carrasco, G; Idris, AI; Li, B; Marino, S; Mollat, P; Ottewell, PD; Sims, AH; Sparatore, A; Wang, N	1
Chen, K; Li, Y; Nong, S; Pan, X; Zhu, X	1
Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA	1
Agarwal, N; Beer, TM; Bergman, AM; Bossi, A; Chen, A; Ciuleanu, TE; Danielli, R; den Eertwegh, AJMV; Drake, CG; Fizazi, K; Franke, FA; Gerritsen, WR; Hansen, S; Houede, N; Korbenfeld, E; Krainer, M; Kwon, ED; Logothetis, C; Mahammedi, H; McHenry, MB; Ng, S; Santos, R; Scher, HI; Sengeløv, L; Sundar, S	1
Fitzpatrick, FC; Sabile, JMG; Skelton, MR; Stump, MS	1
Anzellini, D; De Sanctis, V; Marinelli, L; Massaro, M; Montalto, A; Osti, MF; Reverberi, C; Valeriani, M	1
Adeberg, S; Debus, J; Eichkorn, T; Herfarth, K; Hörner-Rieber, J; König, L; Regnery, S; Schunn, F; Shafie, RE	1
Cook, LM; Frieling, JS; Lawrence, HR; Lawrence, NJ; Li, T; Lo, CH; Lynch, CC; McGuire, JJ; Muhammad, A	1
Ali, A; Amos, C; Attard, G; Brawley, CD; Calvert, J; Clarke, NW; Cook, A; Dearnaley, D; Douis, H; Gillessen, S; Haran, ÁM; Hoyle, A; James, ND; Mason, MD; Parker, CC; Parmar, MKB; Sydes, MR	1
Barwick, B; Boise, L; Chen, HR; Chen, J; Dong, JT; Fu, C; Kowalski, J; Kucuk, O; Li, M; Li, X; Li, Y; Osunkoya, AO; Qian, WP; Vertino, PM; Wu, D; Wu, Q; Xia, S; Xie, L; Yang, L; Zhang, B; Zhao, Y; Zhou, W	1
Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C	1
Achilefu, S; Bakewell, SJ; Cordell, E; Dang, HX; Davis, JL; Esser, AK; Fitzpatrick, JAJ; Fontana, F; Fox, GC; Kwakwa, KA; Lanza, GM; Maher, CA; Pagliai, K; Ross, MH; Sharma, V; Sivapackiam, J; Stewart, SA; Su, X; Veis, DJ; Weilbaecher, KN; Xiang, J; Xu, Y	1
Aoki, Y; Bouvet, M; Hamada, K; Han, Q; Hoffman, RM; Nishida, K; Tome, Y; Wu, NF; Yamamoto, J	1
Chen, Y; Danaher, A; Du, Y; Fu, H; Gera, L; Kucuk, O; Li, X; Liu, D; Lou, L; Mamouni, K; Osunkoya, AO; Sautto, G; Wilson, LM; Wu, D; Xie, ZR; Yang, Y; Zhang, S; Zhou, J	1
Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S	1
Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C	1
Beeker, A; Bloemendal, HJ; de Klerk, JMH; Hoekstra, OS; Jonker, MA; Los, M; O'Sullivan, JM; Oprea-Lager, DE; van den Berg, HP; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW	1
Baldari, S; Boni, G; Bortolus, R; Caffo, O; Conti, G; De Vincentis, G; Monari, F; Procopio, G; Santini, D; Seregni, E; Valdagni, R	1
Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S	1
Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A	1
Miller, K	2
Castañeda, A; Cruz, J; Cruz, O; de Alava, E; de Torres, C; Garcia Del Muro, X; Lopez-Pousa, A; Maradiegue, E; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Mora, J; Perez-Jaume, S; Valverde, C; Vaz, MA	1
Bteich, J; Ernsting, MJ; Hoang, B; Kiyota, T; Li, SD; Tang, WS; Undzys, E	1
Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y	1
Cicero, G; Costa, RP; De Luca, R; Murabito, A; Tripoli, V	1
Heidenreich, A; Nilsson, S; Parker, C; Shore, N	1
Boher, JM; Carducci, MA; Chen, YH; DiPaola, R; Dreicer, R; Eisenberger, MJ; Fizazi, K; Garcia, JA; Gravis, G; Habibian, M; Hussain, MHM; Jarrard, DM; Joly, F; Kohli, M; Liu, G; Oudard, S; Picus, J; Soulie, M; Sweeney, C; Vogelzang, NJ	1
Aymonier, M; Boissier, R; Deville, JL; Ebbo, M; Pourroy, B; Rochigneux, P; Salas, S; Schleinitz, N	1
Gillessen, S; Isensee, G; Müller, J; Omlin, A; Péporté, A; Schmid, S	1
Chen, Y; Du, Y; Fu, H; Kavuri, S; Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y	1
Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I	1
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M	1
Chen, Y; Gera, L; Kucuk, O; Li, X; Liu, H; Mamouni, K; Wu, AY; Wu, D; Yang, Y; Zhang, S	1
Dondossola, E; Friedl, P; Logothetis, CJ; Navone, N; Paindelli, C	1
Aragon-Ching, JB; Finianos, A	1
Amano, H; Onishi, M; Tsunoda, K; Watanabe, A	1
Antonarakis, ES; Carrasquillo, JA; Deandreis, D; Fizazi, K; Higano, CS; Jacene, HA; Loriot, Y; Lu, C; Morris, MJ; Pandit-Taskar, N; Petrenciuc, O; Ryan, CJ; Shevrin, DH; Sweeney, CJ; Vesselle, H	1
Bronich, TK; Cohen, SM; Hyun, MA; Liu, T; Romanova, S; Singh, RK; Wang, S; Zhang, C	1
Abbas, F; Al Dousari, S; Al Hallaq, Y; Al Hamdani, N; Alameh, W; Ashou, R; Assaf, G; Bachir, B; Bitar, N; Bulbul, M; Dagher, C; Dbouk, H; El Khoury, C; El-Hajj, A; Faddoul, S; Farha, G; Farhat, F; Geara, F; Ghazal, H; Gillessen, S; Haidar, M; Hussain, HK; Ibrahim, K; Jabbour, M; Khauli, R; Mukherji, D; Nasr, R; Nemer, E; Omlin, A; Rabah, D; Said, R; Sakr, G; Sayyid, K; Shamseddine, A; Temraz, S; Wazzan, W; Youssef, B; Zouain, N	1
Bai, SB; Cheng, Y; Cui, H; Cui, MX; Liu, DZ; Liu, M; Mei, QB; Zhang, BL; Zhou, SY	1
Hamada, K; Imataka, H; Nemoto, H; Sato, A; Takeda, N	1
Enoki, Y; Fujimoto, S; Fukui, A; Morishita, H; Okuyama, Y; Yoshida, N	1
Lorch, A	1
Fujisawa, Y; Kawachi, Y; Nakamura, Y; Otsuka, F	1
Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S	1
Brown, LG; Corey, E; Kirk, PS; Koreckij, T; Nguyen, HM; Snyder, LA; Vessella, RL	1
Autio, KA; Carrasquillo, JA; Heller, G; Hong, C; Larson, SM; Morris, MJ; Pandit-Taskar, N; Rathkopf, DE; Scher, HI; Slovin, SF; Stephenson, RD	1
Aparicio, AM; Goldkorn, A; Quinn, DI	1
Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ	1
Aggarwal, R; Carducci, M; George, D; Halabi, S; Kantoff, P; Kelly, WK; Mahoney, JF; Millard, F; Monk, JP; Morris, MJ; Small, EJ; Stadler, WM	1
Autio, KA; Basch, EM; Beer, TM; Bennett, AV; Carducci, MA; Fruscione, M; George, DJ; Jia, X; Kane, RC; Logothetis, CJ; Morris, MJ; Rogak, L; Scher, HI; Sit, L	1
de Morrée, ES; de Wit, R; Eisenberger, MA; Shen, L; Tannock, IF; van Soest, RJ	1
Fujimoto, N; Fukumoto, R; Hayashi, T; Koide, T; Oka, D; Soda, T	1
Guo, CY; Han, SH; Song, HP; Yu, L; Zhang, PJ; Zhang, Z	1
Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Minemura, M; Nishikawa, J; Ogawa, K; Sugiyama, T; Ueda, A; Ueda, Y; Yoshita, H	1
Böker, A; Geith, A; Gschwend, JE; Kuczyk, M; Merseburger, AS; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; von Klot, C	1
Hashimoto, Y; Hatakeyama, S; Imai, A; Iwamura, H; Koie, T; Ohyama, C; Tanaka, T; Tanaka, Y; Tokui, N; Yamamoto, H; Yoneyama, T; Yoshikawa, K	1
Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC	1
Taneja, SS	1
Antonarakis, ES; Carducci, MA; Eisenberger, MA; Goyal, J; Nuhn, P; Vaghasia, AM; Zhou, XC	1
Ely, B; Gertz, E; Goldkorn, A; Hussain, M; Lara, PN; Mack, PC; Quinn, DI; Tangen, C; Thompson, IM; Twardowski, PW; Van Loan, MD; Vogelzang, NJ	1
Duncker-Rohr, V; Freund, U; Momm, F	1
Chen, BD; Li, GH; Yu, SC	1
Fizazi, K; Loriot, Y; Massard, C	1
de Riese, W; Filleur, S; Hirsch, J; Lopez, J; Martinez-Marin, D; Miller, B; Nelius, T; Rinard, K	1
Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T	1
Ernsting, MJ; Hoang, B; Li, SD; Murakami, M; Undzys, E	1
Han, KS; Hong, SJ	1
Azad, AA; Chi, KN; Eigl, BJ; Kollmannsberger, C; Murray, RN	1
Bai, B; Cui, Y; Lu, C; Luo, Z	1
Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL	1
Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S	1
Joo, J; Kwon, MM; Lim, KY; Park, BK; Park, HJ; Park, SY; Yoon, JH	1
Chen, W; Jin, H; Pan, Y; Wang, F; Weng, Z; Ye, T; Yu, Z; Zheng, Y	1
Baciuchka, M; Berdah, JF; Beuzeboc, P; Boher, JM; Bousquet, G; Dauba, J; Delva, R; Deplanque, G; El Kouri, C; Eymard, JC; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Krakowski, I; Labourey, JL; Laguerre, B; Latorzeff, I; Linassier, C; Machiels, JP; Marino, P; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulie, M; Suc, E; Théodore, C; Walz, J; Zanetta, S	1
Dass, RN; Diels, J; Ford, D; Hamberg, P; Price, PW; Spencer, M	1
Hara, H; Itaya, N; Nutahara, K; Okegawa, T; Tambo, M	1
Wang, W; Wang, Z; Xiao, X	1
Chen, G; Fan, B; Fan, H; Fu, J; Gao, P; Guo, Z; Hu, Y; Huang, C; Li, J; Li, X; Shi, L; Wang, W; Wang, Z; Wu, S; Wu, Z; Xiao, X; Xu, C; Yu, X; Zhang, H; Zhu, H	1
Den, RB; Kelly, WK	1
Aksnes, AK; Bottomley, D; Fang, F; Helle, SI; Hoskin, P; Johannessen, DC; Logue, J; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Vogelzang, NJ; Wahba, M	1
Gao, JF; Huang, XY; Jing, SF; Li, CD; Wang, DZ; Wei, H	1
Amir, E; de Wit, R; Eisenberger, MA; Mercier, F; Rosenthal, M; Sonpavde, G; Tannock, IF; Templeton, AJ; Tombal, B; van Soest, RJ; Vera-Badillo, FE	1
Gravis, G; Salem, N; Walz, J	1
Barbanti, G; Bianco, V; Brozzetti, S; De Rubertis, G; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G	1
Beer, TM; Efstathiou, E; Forer, D; Higano, CS; Hirmand, M; Scher, HI; Taplin, ME	1
Cho, H; Hanamoto, A; Inohara, H; Nakahara, S; Nishiike, S; Takenaka, Y; Yamamoto, Y; Yasui, T	1
Aldemir, MN; Bilen, N; Bilici, M; Cayir, K; Makas, I; Simsek, M; Tekin, SB; Turkeli, M; Yildirim, N	1
Bhor, M; Bhowmik, D; Hennessy, D; Nicacio, L; Rembert, D; Schnadig, I; Shen, L; Sonpavde, G; Yap, M	1
Fukawa, T; Fukumori, T; Kagawa, J; Kanayama, H; Komori, M; Kusuhara, Y; Mori, H; Takahashi, M; Yamaguchi, K; Yamamoto, Y	1
Akıncı, MB; Aksoy, S; Dede, DS; Ozdemir, NY; Şendur, MA; Ulas, A; Yalçın, B; Zengin, N	1
Alva, AS; Boes, JL; Brisset, JC; Chenevert, TL; Galbán, CJ; Galbán, S; Hoff, BA; Hussain, M; Jacobson, JA; Johnson, TD; Meyer, CR; Nicolay, K; Pienta, KJ; Rehemtulla, A; Ross, BD; Schakel, T	1
Albiges, L; Fizazi, K; Loriot, Y; Massard, C	1
Fizazi, K; Jenkins, C; Tannock, IF	1
Nilsson, S	1
Beuzeboc, P; Massard, C	1
Armstrong, AJ; Li, J	1
Armstrong, AJ; Fandi, A; Petrylak, DP; Pond, GR; Rosenthal, M; Sonpavde, G; Templeton, AJ; Tombal, B	1
Ammannagari, N; Danchaivijitr, P; George, S; Javvaji, C	1
Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T	1
Kim, DH; Kim, MS; Lee, JA; Lim, JS; Paik, EK; Seo, J; Yoo, JY	1
Albiges, L; Burdett, S; Clarke, NW; Fisher, D; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LHM; Sweeney, CJ; Sydes, MR; Tierney, JF; Tombal, B; Vale, CL	1
Hattori, Y; Kawahara, T; Kondo, K; Miyoshi, Y; Moriyama, M; Noguchi, K; Takebayashi, S; Teranishi, J; Uemura, H; Uemura, K; Yao, M; Yokomizo, Y; Yoneyama, S	1
Hattori, Y; Kawahara, T; Kondo, K; Miyoshi, Y; Moriyama, M; Noguchi, K; Takebayashi, S; Teranishi, J; Uemura, H; Yao, M; Yokomizo, Y; Yoneyama, S	1
Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F	1
Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Shan, M; Vogelzang, NJ; Zhan, L	1
Hara, I; Iba, A; Iguchi, T; Kikkawa, K; Kodama, Y; Kohjimoto, Y; Koike, H; Kusumoto, H; Matsumura, N; Yamashita, S	1
Coleman, RE; Hoskin, P; Nilsson, S; Parker, C; Petrenciuc, O; Sartor, O; Staudacher, K; Thuresson, M; Vogelzang, NJ	1
Chen, Z; Gera, L; Kucuk, O; Li, X; Mamouni, K; Wu, D; Zhang, S	1
Ahn, HS; Baek, HJ; Cho, WH; Choi, HS; Im, HJ; Jeon, DG; Kang, HJ; Koh, KN; Koo, HH; Kook, H; Lee, JA; Lee, JW; Lim, YJ; Park, BK; Park, HJ; Park, KD; Seo, JJ; Shin, HY; Song, WS; Sung, KW; Yoo, KH; Yoon, HS	1
Strouthos, I; Tselis, N; Zamboglou, N	1
Azfer, A; Jamil, NS; Salter, DM; Worrell, H	1
Kitawaki, J; Kokabu, T; Konishi, E; Mori, T; Tsukasaki, N; Yasukawa, S	1
Agarwal, N; Alex, A; Heilbrun, ME; Parker, SJ; Pond, GR; Sonpavde, G	1
Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J	1
Hu, Y; Jiang, S; Yu, X; Zu, Y	1
Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S	1
Cheng, T; Chi, KN; Eigl, BJ; Eliasziw, M; North, S; Parimi, S; Ruether, D; Trudeau, M; Winquist, E	1
Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V	1
Bloemendal, HJ; de Klerk, JM; Geldof, AA; Hendrikse, NH; Lange, R; Paap, M; ter Heine, R; Tromp, AM; van Wieringen, WN	1
Chung, HC; Gho, SG; Kim, GM; Kim, SI; Paik, S; Park, HS; Park, S; Sohn, J	1
Aherne, ST; Boland, A; Clynes, M; Doolan, P; Fitzpatrick, JM; Hurley, G; Kay, E; Lundon, DJ; Madden, SF; Morrissey, C; O'Neill, A; Prencipe, M; Watson, RW	1
Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P	1
Choueiri, MB; Do, KA; Kim, J; Lee, YC; Lin, SH; Logothetis, CJ; Mathew, P; Navone, NM; Tu, SM; Wen, S; Ye, X; Yu-Lee, LY	1
Armstrong, A; Canon, J; Dougall, WC; Jones, J; Miller, RE; Roudier, M	1
Asakura, T; Fujinami, K; Goto, A; Jinza, S; Okajima, K; Onuki, T; Senga, Y; Yamashita, Y	1
Braun, M; Deertz, H; Deuss, B; Illiger, HJ; Janssen, J; Küchler, T; Meier, CR; Oeney, HT; Rotermund, S; Steder, M	1
Botti, C; Corsetti, S; Di Lauro, L; Fattoruso, SI; Foggi, P; Giannarelli, D; Giotta, F; Lopez, M; Mottolese, M; Sergi, D; Vici, P; Viola, G	1
Agur, Z; Gorelik, B; Hankins, WD; Shohat, R; Sidransky, D; Wick, M; Ziv, I	1
Ebetino, FH; Lowik, CW; Papapoulos, SE; van Beek, ER; van Wijngaarden, J	1
Elling, D; Heinrich, G; Kittel, K; Klare, P; Kreienberg, R; Krocker, J; Kümmel, S; Lichtenegger, W; Schmid, P; Sommer, H; Steck, T	1
Andrieu, JM; Banu, A; Banu, E; Kacso, G; Levy, E; Medioni, J; Oudard, S; Scotte, F; Wasserman, J	1
Chenevert, TL; Galbán, CJ; Lee, KC; Neeley, C; Nicolay, K; Pienta, KJ; Rehemtulla, A; Ross, BD; Rozel, S; Snyder, LA; Sud, S	1
Carrasquillo, J; Curley, T; Delacruz, A; Divgi, CR; Gignac, GA; Heller, G; Hong, C; Jia, X; Kelly, WK; Larson, S; Morris, MJ; O'Donoghue, J; Pandit-Taskar, N; Rathkopf, D; Scher, HI; Schwartz, L; Slovin, S; Solit, D; Stephenson, RD	1
Beuzeboc, P; Bouzy, J; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Haddad, V; Laplanche, A; Loriot, Y; Lumbroso, J; Massard, C; Theodore, C; Tournay, E	1
Hegele, A; Hofmann, R; Olbert, PJ; Schrader, AJ; Weil, C	1
Gorlick, R; O'Day, K	1
Ahmad, A; Ali, S; Banerjee, S; Kong, D; Rahman, KM; Sakr, WA; Wang, Z	1
Berry, H; Dodwell, DJ; Gillibrand, A; Kumar, S; Perren, TJ; Velikova, G; Waters, SH	1
Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY	1
Feng, ZF; Liu, X; Liu, ZM; Song, HS; Tang, RM	1
Fossella, FV; Glisson, BS; Herbst, RS; Khuri, FR; Kim, ES; Lee, JJ; Lippman, SM; William, WN; Zinner, RG	1
Ikeda, T; Minamoto, K	1
Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM	1
Chen, Z; Corey, DR; Hsieh, JT; Koeneman, KS; Li, Y; Li, ZZ; Malaeb, BS; Shay, JW; Thompson, MG	1
Chen, H; Lin, JR; Xie, B; Xu, ZY; Zhang, WM; Zheng, JH; Zhou, J	1
Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S	1
Efstathiou, E; Logothetis, CJ	1
Almhanna, K; Bekai-Saab, T; Dawson, S; El-Rayes, BF; Hammad, N; Heilbrun, LK; Patel, B; Philip, PA; Shields, AF; Smith, D; Urba, S; Vaishampayan, U; Zalupski, M	1
Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T	1
Berriolo-Riedinger, A; Brunotte, F; Cochet, A; Couturier, O; Girault, S; Rousseau, C	1
Dalhaug, A; Haukland, E; Nieder, C; Pawinski, A	1
Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T	1
Hashine, K; Kusuhara, Y; Miura, N; Numata, K; Shirato, A; Sumiyoshi, Y	1
Azevedo, F; Baudrier, T; Duarte, AF; Ferreira, O; Mota, A	1
Groshen, S; Jadvar, H; Lin, E; Markland, FS; Pinski, J; Swenson, S; Wang, Q; Ye, W	1
Armstrong, AJ; Berry, WR; de Wit, R; Eisenberger, MA; Pond, GR; Sonpavde, G; Tannock, IF	1
Dyck, J; Huizing, MT; Rasschaert, M; Schrijvers, D; Specenier, P; Van den Brande, J; Vermorken, JB; Vroman, P	1
Cheng, JP; Jia, J; Lu, YL; Ren, J; Wang, XY; Yan, Y; Yuan, YH	1
Burris, HA; de Bono, JS; Hubner, A; Miller, K; Morris, T; Nathan, F; Payne, H; Stephenson, J; Taboada, M; Trump, DL	1
Eary, JF; Hackenbracht, JA; Higano, CS; Link, JM; Mankoff, DA; Montgomery, RB; Muzi, M; Rezvani, BB; Yu, EY	1
Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl	1
Mathew, P; Morita, S; Thall, PF; Wen, S	1
Goetz, D	1
Altieri, V; Buonerba, C; Cavaliere, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Ferro, M; Perdonà, S; Puglia, L; Rescigno, P	1
Rexer, H	1
Armstrong, AJ; Berry, WR; Brookes, M; de Wit, R; Eisenberger, MA; Leopold, L; Pond, GR; Sonpavde, G; Tannock, IF; Wood, BA	1
Chen, SZ; Chen, XM; Ding, Y; Mo, KL; Wang, XC; Zhang, F	1
Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH	1
Ahn, JH; Lee, EM; Lee, J; Park, KH; Rha, SY	1
Kanekura, T; Kawai, K; Matsushita, S; Mera, K; Yonekura, K	1
Agrawal, S; Araujo, JC; Armstrong, AJ; Braud, EL; Gallick, GE; Logothetis, CJ; Lonberg, M; Mathew, P; Paliwal, P; Posadas, E; Trudel, GC	1
Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA	1
Kumar, A; Manjappa, AS; Megraj Khandelwal, VK; Mishra, AK; Monkkonen, J; Ramachandra Murthy, RS; Ramanlal Chaudhari, K; Ukawala, M	1
Ben-Ami, T; Gosiengfiao, Y; Reichek, J; Walterhouse, D; Woodman, J	1
Bahl, A; Bellmunt, J; Oudard, S	1
Arranz, JÁ; Cassinello, J; Climent, MA; García-Donas, J; González del Alba, A; León-Mateos, L; Mellado, B; Méndez-Vidal, MJ; Pérez-Valderrama, B; Piulats, JM; Sánchez-Hernández, A	1
Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK	1
Boulaamane, L; Boutayeb, S; Errihani, H	1
Perry, CJ; Sundar, S	1
Fujita, S; Hata, A; Imai, Y; Kaji, R; Katakami, N; Kida, Y; Tanaka, K	1
He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y	1
Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS	1
Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S	1
Alici, S; Alkiş, N; Benekli, M; Berk, V; Büyükberber, S; Camci, C; Coskun, U; Esbah, O; Kaya, AO; Ozdemir, NY; Ozkan, M; Sevinc, A; Ulas, A	1
He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H	1
Berry, JE; Daignault, SD; Eber, MR; Koh, AJ; Li, X; Liao, J; McCauley, LK; Michalski, ME; Nemeth, JA; Park, SI; Pienta, KJ; Sadler, D; Snyder, LA; Soki, FN; Sud, S; Tisdelle, S; Wronski, TJ	1
Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED	1
Bhowmick, NA; Chu, CY; Chung, LW; Fernandez, A; Fritz, G; Jackson, RS; Kitada, S; Pellecchia, M; Placzek, W; Reed, JC; Stebbins, J; Wei, J; Ziaee, S	1
Berardi, R; Bleuse, JP; Cappuzzo, F; de Wit, R; Dogliotti, L; Jannuzzo, MG; Mariani, M; Meulenbeld, HJ; Petroccione, A; Raymond, E; Santoro, A; Sternberg, CN; Tagawa, ST; Vinci, EM; Vitali, G	1
Meisel, A; Stenner, F	1
Ananias, HJ; de Jong, IJ; De Vries, EG; Domanska, UM; Huls, G; Kliphuis, NM; Kruizinga, RC; Nagengast, WB; Oude Munnink, TH; Timmer-Bosscha, H; Walenkamp, AM	1
Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C	1
Goto, K; Kubota, K; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K	1
Blom, R; Bolstad, B; Bruland, ØS; Franzén, L; Johannessen, DC; Lennernäs, B; Nilsson, S; O'Bryan-Tear, CG; Parker, C; Petersson, U; Pigott, K; Sokal, M; Tennvall, J; Thuresson, M; Tyrrell, C	1
Penson, DF; Resnick, MJ	1
Cheng, HH; Lin, DW; Yu, EY	1
Guven, M; Inal, A; Işikdogan, A; Kaplan, MA; Kuçukoner, M; Nas, N; Urakci, Z; Yunce, M	1
Hayashi, N; Kawahara, T; Kubota, Y; Misaki, H; Miyoshi, Y; Noguchi, K; Sano, F; Sekiguchi, Z; Teranishi, J; Uemura, H	1
Dai, B; Kong, YY; Ma, CG; Qu, YY; Yang, WY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL	1
Harita, S; Kiguchi, T; Kimura, K; Kubo, T; Mannami, T; Masunari, T; Nakata, Y; Ninomiya, K; Okada, T; Seno, S; Sezaki, N; Sonobe, H; Suzuki, Y; Tamura, T	1
Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB	1
Lim, YL; Tay, EY	1
Attarian, H; Ghadyani, M; Haghighi, S; Rezvani, H	1
Petrányi, Á	1
Jiang, ZF; Ma, Y; Meng, XY; Song, ST; Sun, B; Wang, T; Wu, SK; Zhang, SH	1
Kawai, N; Kobayashi, D; Kobayashi, T; Kohri, K; Naiki, T; Sato, S; Takahashi, S; Tozawa, K; Yamada, K; Yasui, T	1
Yu, EY; Zhao, S	1
Avancès, C; Culine, S; Jacot, W; Sénesse, P	1
Aida, Y; Chishima, Y; Kitajima, A; Noro, M; Okamoto, H; Satou, Y; Takano, S	1
Krempien, R; Piroth, MD; Wannenmacher, M; Zierhut, D	1
Abebe, L; Bhagwati, N; Jain, D; Marcoullis, G; Talusan, R; Wiernik, PH	1
Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I	1
Conte, PF; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B	1
Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M	1
Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S	1
Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M	1
Chan, SY; Sundar, S	1
Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R	1
Beer, TM; Eilers, KM; Garzotto, M; Henner, WD; Wersinger, EM	2
Akaza, H; Hattori, K; Hinotsu, S; Kawai, K; Kojima, T; Miyanaga, N; Onozawa, M; Shimazui, T; Tsukamoto, S	1
Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M	1
Alonso, G; Amenedo, M; Curiel, T; Fírvida, JL; Grande, C; Huidobro, G; Lázaro, M; Mel, JR; Ramos, M; Vázquez, S	1
Itoh, S; Mitsuhata, N; Watanabe, Y	2
Fidler, IJ; Logothetis, CJ; Mathew, P	1
Bucana, C; Fidler, IJ; Jones, D; Kim, SJ; Logothetis, C; Mathew, P; Perez, C; Thall, PF; Troncoso, P	1
Abbou, CC; Allory, Y; Chopin, D; de la Taille, A; Hoznek, A; Paule, B; Salomon, L; Vacherot, F; Vordos, D; Yiou, R	1
España, L; Gu, B; Méndez, O; Sierra, A; Torregrosa, A	1
Chuman, H	1
Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D	1
Taniguchi, M; Watanabe, A	1
Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K	1
Bang, SM; Cho, EK; Lee, JH; Lee, YD; Park, SH; Shin, DB	1
Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K	1
Abdellatif, M; Chandra, R; Korah, R; Najmi, S; Wieder, R	1
Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J	1
Carboni, R; Caristi, N; Chiofalo, G; La Torre, F; Mafodda, A; Maisano, R; Mare, M; Picciotto, M	1
Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M	1
Higano, CS	1
Hamai, Y; Hihara, J; Tanabe, K; Toge, T; Ukon, K; Yoshida, K	1
Beer, TM; Garzotto, M; Ryan, CW; Tiffany, NM; Wersinger, EM	1
Harmenberg, U; Hjelm-Eriksson, M; Kälkner, KM; Lennartsson, L; Lennernäs, B; Nilsson, S; Ullén, A	1
Fukata, S; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Nomura, A; Ohtsuki, Y; Shuin, T	1
Bighin, C; Cappuzzo, F; Del Mastro, L; Durando, A; Lambiase, A; Monfardini, S; Nicoletto, O; Olmeo, N; Puglisi, F; Venturini, M	1
De Lena, M; Leone, B; Lorusso, V; Numico, G; Silvestris, N	1
Brown, LG; Brubaker, KD; Corey, E; Vessella, RL	1
Clemons, M; Gainford, MC	1
Abrams, J; Cher, ML; Hussain, M; Kucuk, O; Li, Y; Sarkar, FH	1
Ando, J; Asaga, T; Fujii, H; Inoue, K; Kimura, M; Kurosumi, M; Sano, M; Sato, N; Tabei, T; Yamamoto, N	1
Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K	1
Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y	1
Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV	1
Bloomfield, D; James, ND; Luscombe, C	1
Katakami, N	1
Albanell, J; Bosch, M; Campás, C; Codony-Servat, J; Dang, L; Domingo-Domenech, J; Filella, X; Gascon, P; Mellado, B; Montagut, C; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, M	1
Akamatsu, H; Imazu, Y; Koshida, Y; Motegi, K; Murayama, T; Ohyama, R; Toeda, H; Toriumi, F; Yoneyama, K	1
Blanc-Fournier, C; Chasle, J; Guedin, P; Lacroix, J	1
Sweeney, CJ	1
Iwama, T; Karasawa, K; Kato, K; Sato, S; Sato, T; Takahashi, T; Tsunozaki, H	1
Suzuki, M	1
Tombal, B	1
Arbiser, JL; Chung, LW; Fujisawa, M; Gotoh, A; Johnstone, PA; Shigemura, K; Sun, SY; Weksler, B; Zayzafoon, M; Zhau, HE	1
Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G	1
Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM	1
Chenevert, TL; Lee, KC; Meyer, CR; Moffat, BA; Pienta, KJ; Rehemtulla, A; Ross, BD; Sud, S	1
Banerjee, S; Bonfil, D; Che, M; Cher, M; Hussain, M; Saliganan, A; Sarkar, FH; Wang, Z	1
Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S	1
Kovel, S; Sella, A; Skoneczna, I; Sternberg, C; Yarom, N	1
Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA	1
Baur, M; Coombes, RC; Diéras, V; Dittrich, C; Hatschek, T; Hudec, M; Klink-Alakl, M; Murawsky, M; Tubiana-Hulin, M; van Oosterom, AT	1
Bubley, G; Derynck, MK; Lin, AM; Park, M; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V	1
Masuda, N	1
Armstrong, AJ; Carducci, MA; de Wit, R; Eisenberger, M; Garrett-Mayer, E; Ou Yang, YC; Tannock, I	1
Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC	1
Bucana, CD; Cohen, L; Fidler, IJ; Johnson, MM; Jones, DM; Kim, SJ; Logothetis, CJ; Mathew, P; Meluch, AA; Morris, MJ; Oh, WK; Pagliaro, LC; Smith, L; Tannir, NM; Thall, PF; Troncoso, P; Tu, SM; Wen, S	1
Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H	1
Alfaro, J; Carles, J; Catalan, G; Domenech, M; Font, A; Gallardo, E; Gonzalez Del Alba, A; González-Larriba, JL; Lianes, P; Mellado, B; Nogué, M; Tello, JM	1
de Lemos, ML; Ellard, S; Hu, F; Kuik, K; Olivotto, IA; Speers, CH; Taylor, SC; Vu, T	1
Chung, LW; Fuji, K; Fujisawa, M; Gardner, TA; Gotoh, A; Hamada, K; Hara, I; Higashihara, E; Hinata, N; Kamidono, S; Kao, C; Matsuo, M; Okegawa, T; Shirakawa, T; Sugimura, K; Takenaka, A; Tanaka, K; Terao, S	1
Miki, T; Okihara, K	1
Autorino, R; De Placido, S; Di Lorenzo, G; Figg, WD; Fossa, SD; Giordano, A; Giuliano, M; Imbimbo, C; Labianca, R; Longo, N; Mirone, V; Perdonà, S	1
Dai, JL; Daignault, S; Day, ML; Dougall, W; Escara-Wilke, JF; Ignatoski, KM; Keller, ET; Lui, A; Sargent, EE; Yao, Z; Zhang, J	1
Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R	1
Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL	1
Ardine, M; Berruti, A; Dogliotti, L; Mosca, A; Poggio, M; Russo, L; Saini, A; Tucci, M; Vana, F	1
Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T	1
Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T	1
Kennedy, MJ	1
Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V	1
Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S	1
Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G	1
Anibali-Charpiat, MF; Calluaud, L; Fabre-Guillevin, E; Ravaud, A; Tchen, N	1
Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB	1
Feenstra, J; Stricker, BH; Vermeer, RJ	1
Endo, T; Fujimoto, K; Haseyama, Y; Koike, T; Koizumi, K; Nishio, M; Sawada, K; Takashima, H; Yamamoto, S	1
Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M	1
Aydiner, A; Karadeniz, A; Sakar, B; Tas, F; Tenekeci, N; Topuz, E	1
Ikeda, H; Koshiba, R	1
Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T	1
Ishikawa, T; Itasaka, H; Kume, K; Matsusaka, T; Ohshiro, T; Ohta, M; Sonoda, K; Tashiro, H; Yamamura, S	1
Ishihama, H	1
Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Hamm, C; Karanes, C; Klein, JL; Peters, WP	1
Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M	1
Caruso, A; De Carolis, S; De Santis, M; Ferrazani, S; Lucchese, A	1
Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K	1
Beer, TM; Bubalo, JS	1

Reviews

37 review(s) available for docetaxel anhydrous and Bone Neoplasms

Article	Year
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary. Future oncology (London, England), 2023, Volume: 19, Issue:15 Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium	2023
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Critical reviews in oncology/hematology, 2020, Volume: 146 Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment	2020
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. Critical reviews in oncology/hematology, 2017, Volume: 113 Topics: Bone Neoplasms; Disease Management; Docetaxel; Humans; Italy; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Treatment Outcome	2017
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:8 Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids	2017
[Review on quality of life in CRPC patients]. Aktuelle Urologie, 2017, Volume: 48, Issue:3 Topics: Abiraterone Acetate; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival Rate; Treatment Outcome	2017
Current approaches to incorporation of radium-223 in clinical practice. Prostate cancer and prostatic diseases, 2018, Volume: 21, Issue:1 Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome	2018
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European urology, 2018, Volume: 73, Issue:6 Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tumor Burden	2018
Acute myositis: an unusual and severe side effect of docetaxel: a case report and literature review. Anti-cancer drugs, 2018, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Myositis; Prostatic Neoplasms, Castration-Resistant	2018
Zoledronic acid for the treatment of prostate cancer. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:6 Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid	2019
[Metastatic prostate cancer: new insights and developments]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:14 Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids	2013
[Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2014, Volume: 43, Issue:1 Topics: Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma. Paediatric drugs, 2014, Volume: 16, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids	2014
[Metastatic hormone-sensitive prostate cancer]. Bulletin du cancer, 2015, Volume: 102, Issue:1 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Combined Modality Therapy; Docetaxel; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Taxoids	2015
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Proportional Hazards Models; Prostatic Neoplasms; Standard of Care; Taxoids	2015
[How to manage patients with CRPC?]. Bulletin du cancer, 2015, Volume: 102, Issue:6 Topics: Abiraterone Acetate; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Tissue Extracts	2015
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet. Oncology, 2016, Volume: 17, Issue:2 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Survival Rate; Taxoids; Zoledronic Acid	2016
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer treatment reviews, 2016, Volume: 44 Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid	2016
Docetaxel-induced radiation recall dermatitis : A case report and literature review. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016, Volume: 192, Issue:10 Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Histamine Antagonists; Humans; Male; Radiation Tolerance; Radiodermatitis; Taxoids; Treatment Outcome	2016
Novel therapeutic agents for osteosarcoma. Expert review of anticancer therapy, 2009, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Docetaxel; Dogs; Drug Delivery Systems; Folic Acid Antagonists; Gemcitabine; Humans; Immunologic Factors; Neoadjuvant Therapy; Neoplasm Proteins; Osteosarcoma; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Survival Rate; Taxoids; Xenograft Model Antitumor Assays; Young Adult	2009
New options for the management of castration-resistant prostate cancer: a case perspective. Journal of the National Comprehensive Cancer Network : JNCCN, 2011, Volume: 9 Suppl 3 Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome	2011
[Castration resistant prostate cancer 2011]. Aktuelle Urologie, 2011, Volume: 42, Issue:2 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts	2011
[Strategy in advanced castration-resistant prostate cancer]. Bulletin du cancer, 2012, Volume: 99 Suppl 1 Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid	2012
[New drug treatment possibilities in castration resistant prostate carcinoma]. Praxis, 2012, Sep-05, Volume: 101, Issue:18 Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Lung Neoplasms; Male; Orchiectomy; Palliative Care; Prognosis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids	2012
Quality of life with advanced metastatic prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid	2012
Advanced clinical states in prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Cancer Vaccines; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts	2012
[The treatment of castration-resistant prostate cancer]. Magyar onkologia, 2012, Volume: 56, Issue:4 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cancer Vaccines; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Oligonucleotides, Antisense; Orchiectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; RANK Ligand; Receptors, Vascular Endothelial Growth Factor; Taxoids; Tissue Extracts; Treatment Failure	2012
[Therapy for hormone-refractory prostate cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome	2002
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. International journal of clinical oncology, 2003, Volume: 8, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2003
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids	2004
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids	2004
Current status of treatment for patients with metastatic prostate cancer. The Canadian journal of urology, 2005, Volume: 12 Suppl 2 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Docetaxel; Drug Monitoring; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2005
Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology, 2005, Volume: 69, Issue:4 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome	2005
The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate cancer and prostatic diseases, 2006, Volume: 9, Issue:3 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisolone; Prostatic Neoplasms; Spinal Cord Compression; Taxoids; Urologic Diseases	2006
[Optimal chemotherapy for advanced and recurrent breast cancer patients]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab	2007
[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoporosis; Practice Guidelines as Topic; Prognosis; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Zoledronic Acid	2007
Metastatic breast cancer. Current opinion in oncology, 1996, Volume: 8, Issue:6 Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome	1996
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Current urology reports, 2002, Volume: 3, Issue:3 Topics: Aged; Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Male; Paclitaxel; Pain; Prostatic Neoplasms; Taxoids	2002

Trials

96 trial(s) available for docetaxel anhydrous and Bone Neoplasms

Article	Year
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatric blood & cancer, 2021, Volume: 68, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Docetaxel; Humans; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing	2021
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. JAMA oncology, 2020, 02-01, Volume: 6, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. European urology, 2020, Volume: 78, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Ipilimumab; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Time Factors	2020
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology, 2021, Apr-01, Volume: 7, Issue:4 Topics: Aged; Androgen Antagonists; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate; Prostatic Neoplasms	2021
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting	2017
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). British journal of cancer, 2017, Sep-05, Volume: 117, Issue:6 Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Odds Ratio; Prognosis; Prospective Studies; Sarcoma, Ewing; Spain; Survival Rate; Taxoids	2017
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC cancer, 2019, Jan-07, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome	2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European journal of cancer (Oxford, England : 1990), 2019, Volume: 114 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium	2019
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids	2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer, 2013, Oct-15, Volume: 119, Issue:20 Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; International Agencies; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids	2013
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. European urology, 2014, Volume: 66, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Bone Neoplasms; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Staging; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids	2014
[Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult	2013
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Taxoids; Treatment Failure; Vomiting	2016
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Collagen Type I; Disease-Free Survival; Docetaxel; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; ROC Curve; Taxoids; Treatment Failure	2014
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer science, 2014, Volume: 105, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease-Free Survival; Docetaxel; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid	2014
A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. BMC cancer, 2014, Aug-28, Volume: 14 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Ewing; Taxoids; Young Adult	2014
Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. International urology and nephrology, 2014, Volume: 46, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome; Zoledronic Acid	2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. European urology, 2015, Volume: 68, Issue:2 Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Decision Support Techniques; Docetaxel; France; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Nomograms; Orchiectomy; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Reproducibility of Results; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2015
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC The Lancet. Oncology, 2014, Volume: 15, Issue:12 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids	2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Follow-Up Studies; Humans; International Agencies; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutrophils; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids	2015
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:3 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome	2015
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European urology, 2015, Volume: 68, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids	2015
Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer. PloS one, 2015, Volume: 10, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Density; Bone Neoplasms; Diffusion Magnetic Resonance Imaging; Diphosphonates; Disease Models, Animal; Docetaxel; Humans; Male; Mice; Multimodal Imaging; Osteoblasts; Osteolysis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Tumor Burden	2015
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert opinion on drug safety, 2015, Volume: 14, Issue:7 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Neoplasms; Bone Remodeling; Collagen Type I; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Taxoids; Treatment Outcome	2015
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5 Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Standard of Care; Taxoids; Treatment Outcome	2016
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. The Prostate, 2016, Volume: 76, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Treatment Outcome	2016
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health technology assessment (Winchester, England), 2016, Volume: 20, Issue:53 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid	2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational new drugs, 2016, Volume: 34, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Management; Docetaxel; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Sunitinib; Survival Rate; Taxoids	2016
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. The Lancet. Oncology, 2017, Volume: 18, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thionucleotides	2017
Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment. Onkologie, 2008, Volume: 31, Issue:8-9 Topics: Adult; Aged; Anthracyclines; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Taxoids; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine	2008
A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology, 2008, Volume: 75, Issue:3-4 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Salvage Therapy; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2008
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prognosis; Safety; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2009
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU international, 2009, Volume: 103, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Pain; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Treatment Outcome	2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids	2009
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15 Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Pain Measurement; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids	2009
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer]. Aktuelle Urologie, 2009, Volume: 40, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Survival Rate; Taxoids	2009
[Efficacy of hypofractionated radiotherapy combined with docetaxel for treatment of bone metastasis of lung cancer]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:7 Topics: Adult; Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Taxoids; Treatment Outcome	2009
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. American journal of clinical oncology, 2010, Volume: 33, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2010
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; International Agencies; Liver Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Soft Tissue Neoplasms; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult	2010
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. American journal of clinical oncology, 2011, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2011
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Docetaxel; Esophagogastric Junction; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2010
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2010, Volume: 23, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Interactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome	2010
Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Japanese journal of clinical oncology, 2010, Volume: 40, Issue:11 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2010
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. American journal of clinical oncology, 2011, Volume: 34, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome	2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The Prostate, 2011, Volume: 71, Issue:12 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Orchiectomy; Pain; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome	2011
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clinical nuclear medicine, 2011, Volume: 36, Issue:3 Topics: Acetates; Bone Neoplasms; Carbon; Docetaxel; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids; Treatment Outcome	2011
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2011, Feb-18, Volume: 43, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa	2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2011, Volume: 31, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Bone Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Imatinib Mesylate; Male; Piperazines; Placenta Growth Factor; Pregnancy Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Taxoids	2011
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Failure	2011
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer]. Der Urologe. Ausg. A, 2011, Volume: 50, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Germany; Humans; Male; Oligonucleotides, Antisense; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thionucleotides	2011
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:11 Topics: Aged; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Orchiectomy; Organometallic Compounds; Prostatic Neoplasms; Radiotherapy Dosage; Taxoids; Treatment Outcome	2011
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sarcoma; Taxoids; Young Adult	2012
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer, 2012, Jan-01, Volume: 118, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Dasatinib; Docetaxel; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles	2012
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Treatment Outcome	2012
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. The oncologist, 2012, Volume: 17, Issue:3 Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids	2012
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British journal of cancer, 2012, Apr-24, Volume: 106, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult	2012
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU international, 2013, Volume: 111, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Neoplasms; Castration; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Taxoids; Treatment Failure	2013
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid	2012
Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. PloS one, 2012, Volume: 7, Issue:10 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Long-Term Care; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome	2012
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer. Urology journal, 2012,Fall, Volume: 9, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thalidomide	2012
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Clinical breast cancer, 2002, Volume: 3, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Pilot Projects; Risk Assessment; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids	2002
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, 2003, Mar-01, Volume: 97, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome	2003
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine	2003
Intermittent chemotherapy in metastatic androgen-independent prostate cancer. British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Dexamethasone; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids	2003
Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anti-cancer drugs, 2004, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Endpoint Determination; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Survival Rate; Taxoids; Treatment Outcome	2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-15, Volume: 22, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Taxoids	2004
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU international, 2004, Volume: 94, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid	2004
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2 Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Soft Tissue Neoplasms; Taxoids; Thrombocytopenia; Urologic Neoplasms	2005
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. BMC cancer, 2005, Feb-22, Volume: 5 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids	2005
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids	2005
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1 Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2006
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. The Journal of urology, 2005, Volume: 174, Issue:3 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome	2005
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast cancer research and treatment, 2006, Volume: 95, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab	2006
Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast cancer (Tokyo, Japan), 2006, Volume: 13, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Respiratory Tract Neoplasms; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome	2006
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Taxoids	2006
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids	2006
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Survival; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Interleukin-6; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Statistics as Topic; Survival Analysis; Taxoids; Tumor Cells, Cultured	2006
ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8 Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome	2006
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. European urology, 2007, Volume: 52, Issue:4 Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid	2007
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Taxoids	2007
A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:2 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Retrospective Studies; Taxoids	2008
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clinical genitourinary cancer, 2007, Volume: 5, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Survival Rate; Taxoids; Treatment Outcome	2007
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Comorbidity; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Pain; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids	2007
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Investigational new drugs, 2008, Volume: 26, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid	2008
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Castration; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Placebos; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Taxoids	2007
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. British journal of cancer, 2007, Nov-05, Volume: 97, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Taxoids	2007
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Human gene therapy, 2007, Volume: 18, Issue:12 Topics: Acyclovir; Adenoviridae; Aged; Androgen Antagonists; Antineoplastic Agents; Antiviral Agents; Bone and Bones; Bone Neoplasms; Docetaxel; Genetic Therapy; Genetic Vectors; Humans; Male; Middle Aged; Osteocalcin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Thymidine Kinase; Valacyclovir; Valine	2007
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. European urology, 2008, Volume: 54, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Hormones; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2008
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:15 Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome	1994
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. British journal of cancer, 1996, Volume: 73, Issue:2 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests	1996
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome	1999
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4 Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids	2000
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuro endocrinology letters, 2001, Volume: 22, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids	2001
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology, 2002, Volume: 62, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization	2002

Other Studies

201 other study(ies) available for docetaxel anhydrous and Bone Neoplasms

Article	Year
Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. Anticancer research, 2022, Volume: 42, Issue:3 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Databases, Factual; Docetaxel; Humans; Japan; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Recurrence; Taxoids; Time Factors; Treatment Outcome	2022
Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment. Drug delivery, 2022, Volume: 29, Issue:1 Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostate; Prostatic Neoplasms; Tumor Microenvironment	2022
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis. Anticancer research, 2022, Volume: 42, Issue:6 Topics: Bone Neoplasms; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2022
Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer: A retrospective cohort study. PloS one, 2022, Volume: 17, Issue:6 Topics: Aldehyde Dehydrogenase, Mitochondrial; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Docetaxel; Female; Humans; Retrospective Studies	2022
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis. International journal of pharmaceutics, 2022, Sep-25, Volume: 625 Topics: Alendronate; Bone Neoplasms; Diterpenes; Docetaxel; Epoxy Compounds; Humans; Phenanthrenes	2022
Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel. Anticancer research, 2022, Volume: 42, Issue:10 Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome	2022
Synergistic effect of docetaxel and gambogic acid on bone metastasis of lung cancer. Bulletin du cancer, 2023, Volume: 110, Issue:5 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Docetaxel; Lung Neoplasms; Mice; Taxoids	2023
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression. Acta biomaterialia, 2023, Volume: 166 Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid	2023
A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis. The Prostate, 2023, Volume: 83, Issue:13 Topics: Animals; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Humans; Interleukin-2; Ki-67 Antigen; Male; Mice; Prostatic Neoplasms; Receptors, CXCR4; Tartrate-Resistant Acid Phosphatase	2023
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:7 Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2019
What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO? Oncology (Williston Park, N.Y.), 2019, 08-23, Volume: 33, Issue:8 Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bone Neoplasms; Brain Neoplasms; Carboplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pemetrexed; Prognosis	2019
Metastatic Prostate Cancer Presenting With Bilateral Inguinal Lymphadenopathy. Clinical genitourinary cancer, 2019, Volume: 17, Issue:6 Topics: Biopsy; Bone Neoplasms; Docetaxel; Humans; Inguinal Canal; Lymph Nodes; Lymphadenopathy; Lymphatic Metastasis; Male; Middle Aged; Multiparametric Magnetic Resonance Imaging; Neoplasm Grading; Prostate; Prostatic Neoplasms; Radionuclide Imaging	2019
Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. Biomaterials, 2020, Volume: 227 Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Neoplasm Recurrence, Local; Prostatic Neoplasms; RANK Ligand; Tissue Distribution; Tumor Microenvironment	2020
Hyperpolarized Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbon Isotopes; Carboplatin; Docetaxel; Feasibility Studies; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Prognosis; Prostatic Neoplasms; Pyruvic Acid; Survival Rate	2020
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. British journal of cancer, 2019, Volume: 121, Issue:12 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2019
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. International journal of cancer, 2020, 08-15, Volume: 147, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids	2020
Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth. Cells, 2019, Dec-20, Volume: 9, Issue:1 Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; E-Selectin; Glycolipids; Humans; Male; Mice; PC-3 Cells; Peptides; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Small Molecule Libraries; Xenograft Model Antitumor Assays	2019
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? The Prostate, 2020, Volume: 80, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2020
Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer. Nanomedicine (London, England), 2020, Volume: 15, Issue:9 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Lung Neoplasms; Mice; Nanoparticles; Polyamines	2020
Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer letters, 2020, 09-28, Volume: 488 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Osteolysis; TNF Receptor-Associated Factor 6	2020
Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis. Medical science monitor : international medical journal of experimental and clinical research, 2020, Jun-15, Volume: 26 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prognosis; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate	2020
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic. Oncology (Williston Park, N.Y.), 2020, 08-12, Volume: 34, Issue:8 Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid	2020
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel. JCO oncology practice, 2021, Volume: 17, Issue:2 Topics: Bone Marrow; Bone Neoplasms; Deoxycytidine; Docetaxel; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans	2021
Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer. Scientific reports, 2020, 10-15, Volume: 10, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Recurrence; Retrospective Studies; Tumor Burden	2020
Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2021, Volume: 197, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Hypericum; Lung Neoplasms; Middle Aged; Phytochemicals; Ramucirumab	2021
Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nature communications, 2021, 02-01, Volume: 12, Issue:1 Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Apoptosis; Benzenesulfonates; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Culture Media, Conditioned; Disease Models, Animal; Docetaxel; Humans; Interferons; Male; Mesenchymal Stem Cells; Mice, Knockout; Osteoblasts; Primary Cell Culture; Prostatic Neoplasms; Receptors, Interferon; Recombinant Proteins; RNA, Small Interfering; STAT1 Transcription Factor; STAT3 Transcription Factor; Tibia	2021
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nature communications, 2021, 03-17, Volume: 12, Issue:1 Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclams; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Interleukin-11; Kruppel-Like Transcription Factors; Male; Mice; Mutation; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Signal Transduction; Transforming Growth Factor beta	2021
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without Cancer biotherapy & radiopharmaceuticals, 2021, Volume: 36, Issue:5 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids	2021
Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases. Molecular cancer therapeutics, 2021, Volume: 20, Issue:6 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Integrin beta3; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Survival Analysis	2021
Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model. Anticancer research, 2021, Volume: 41, Issue:4 Topics: Administration, Oral; Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbon-Sulfur Lyases; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Osteosarcoma; Recombinant Proteins; Tibia; Xenograft Model Antitumor Assays	2021
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics, 2021, Volume: 11, Issue:14 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Discovery; Drug Resistance, Neoplasm; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Humans; Inhibitory Concentration 50; Male; Mice; Polycomb Repressive Complex 2; Prostatic Neoplasms; S-Phase Kinase-Associated Proteins; Signal Transduction; STAT3 Transcription Factor; Survivin; Xenograft Model Antitumor Assays	2021
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study. European journal of cancer (Oxford, England : 1990), 2021, Volume: 157 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2021
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PloS one, 2017, Volume: 12, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult	2017
Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. Cancer letters, 2017, 12-01, Volume: 410 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboxymethylcellulose Sodium; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neutropenia; Particle Size; Prostatic Neoplasms, Castration-Resistant; Solubility; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays	2017
Mifepristone Has Limited Activity to Enhance the Anticancer research, 2017, Volume: 37, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Cell Proliferation; Docetaxel; Hormone Antagonists; Humans; Male; Mice; Mifepristone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. Oncology, 2018, Volume: 94, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Italy; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Taxoids	2018
Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223? Clinical genitourinary cancer, 2018, Volume: 16, Issue:5 Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2018
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer. Molecular cancer therapeutics, 2018, Volume: 17, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bromocriptine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Docetaxel; Dopamine Agonists; Drug Repositioning; Drug Synergism; Humans; Male; Mice, Nude; Prostatic Neoplasms; Receptors, Dopamine D2; Xenograft Model Antitumor Assays	2018
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. International urology and nephrology, 2018, Volume: 50, Issue:10 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids	2018
Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. Cancer letters, 2019, 04-01, Volume: 446 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bone Neoplasms; Bradykinin Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Organophosphonates; Phosphorylation; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Survivin; Tumor Burden; Xenograft Model Antitumor Assays	2019
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials, 2019, Volume: 197 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Humans; Male; Mice, SCID; PC-3 Cells; Prostatic Neoplasms; Radium; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment	2019
Meningeal Carcinomatosis in Advanced Extramammary Paget's Disease: A Case Report. Acta dermato-venereologica, 2019, Jul-01, Volume: 99, Issue:9 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Cranial Irradiation; Docetaxel; Female; Genital Neoplasms, Female; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Paget Disease, Extramammary; Spinal Puncture; Treatment Outcome	2019
Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. Molecular pharmaceutics, 2019, 07-01, Volume: 16, Issue:7 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Liberation; Female; Mice; Mice, Inbred BALB C; Micelles; Polymers; RAW 264.7 Cells; Transplantation, Homologous; Treatment Outcome	2019
Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. World journal of urology, 2020, Volume: 38, Issue:3 Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Biopsy, Large-Core Needle; Bone Neoplasms; Docetaxel; Endosonography; Health Resources; Health Services Accessibility; Humans; Iraq; Kallikreins; Kuwait; Lebanon; Lymph Node Excision; Magnetic Resonance Imaging; Male; Margins of Excision; Middle East; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Risk; Salvage Therapy; Saudi Arabia; Syria	2020
Osteoclasts and tumor cells dual targeting nanoparticle to treat bone metastases of lung cancer. Nanomedicine : nanotechnology, biology, and medicine, 2019, Volume: 21 Topics: Animals; Bone Neoplasms; Cell Proliferation; Docetaxel; Drug Delivery Systems; Drug Liberation; Heterografts; Humans; Lung Neoplasms; Mice; Nanoparticles; Neoplasm Metastasis; Osteoclasts; Osteolysis; RAW 264.7 Cells	2019
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Disease Progression; Disseminated Intravascular Coagulation; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur	2013
A large cell neuroendocrine carcinoma of the gall bladder: diagnosis with 18FDG-PET/CT-guided biliary cytology and treatment with combined chemotherapy achieved a long-term stable condition. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Fatal Outcome; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Immunohistochemistry; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Failure	2013
Docetaxel was effective in the management of metastatic angiosarcoma associated with disseminated intravascular coagulation syndrome. International journal of dermatology, 2014, Volume: 53, Issue:2 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Disseminated Intravascular Coagulation; Docetaxel; Hemangiosarcoma; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Splenic Neoplasms; Taxoids	2014
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7 Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome	2013
Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. International journal of molecular sciences, 2013, May-21, Volume: 14, Issue:5 Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Density; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Docetaxel; Humans; Immunohistochemistry; Male; Mice, SCID; Prostate-Specific Antigen; Prostatic Neoplasms; Signal Transduction; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer, 2013, Sep-01, Volume: 119, Issue:17 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Platelet Count; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome	2013
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7 Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids	2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. Journal of oncology practice, 2013, Volume: 9, Issue:5 Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Pain; Patient Outcome Assessment; Prevalence; Prostatic Neoplasms; Self Report; Taxoids	2013
[Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess]. Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:9 Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drainage; Fatal Outcome; Humans; Imidazoles; Jaw; Male; Prostatic Neoplasms; Retropharyngeal Abscess; Taxoids; Tomography, X-Ray Computed; Zoledronic Acid	2013
Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Advances in therapy, 2014, Volume: 31, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure	2014
A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy. BMC research notes, 2014, Jan-29, Volume: 7 Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy, Needle; Bone Neoplasms; Diagnostic Imaging; Disseminated Intravascular Coagulation; Docetaxel; Drug Resistance, Neoplasm; False Negative Reactions; Fatal Outcome; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Unknown Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Transurethral Resection of Prostate	2014
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. European urology, 2014, Volume: 66, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome	2014
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Journal of urology, 2014, Volume: 191, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids	2014
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU international, 2014, Volume: 114, Issue:6b Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neutrophils; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids	2014
Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014, Volume: 190, Issue:5 Topics: Antineoplastic Agents; Antioxidants; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Ointments; Prostatic Neoplasms; Radiodermatitis; Taxoids	2014
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients? European urology, 2014, Volume: 66, Issue:4 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Lung Neoplasms; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell death & disease, 2014, May-08, Volume: 5 Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Eye Proteins; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Nerve Growth Factors; Prostatic Neoplasms, Castration-Resistant; Serpins; Taxoids; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2014
Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. International journal of pharmaceutics, 2014, Aug-25, Volume: 471, Issue:1-2 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Carboxymethylcellulose Sodium; Cell Line, Tumor; Docetaxel; Drug Carriers; Gene Expression; Humans; Male; Mice, Inbred BALB C; Nanoparticles; Particle Size; Prostatic Neoplasms, Castration-Resistant; Surface Properties; Survival Analysis; Taxoids; Xenograft Model Antitumor Assays	2014
Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:10 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Calcium; Disease Progression; Disease-Free Survival; Docetaxel; Follow-Up Studies; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Neoplasm Grading; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2014
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. European urology, 2015, Volume: 67, Issue:1 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids	2015
[Feasibility analysis of endostatin combined with chemotherapy in the treatment of metastatic angiosarcoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Endostatins; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Liver Neoplasms; Male; Middle Aged; Pubic Bone; Taxoids	2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. The Prostate, 2014, Volume: 74, Issue:13 Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2014
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World journal of urology, 2015, Volume: 33, Issue:6 Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate	2015
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:3 Topics: Adrenal Cortex Hormones; Aged; Algorithms; Antineoplastic Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Docetaxel; Europe; Health Status; Humans; Male; Models, Theoretical; Pain; Pain Management; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Taxoids	2015
Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer research, 2014, Volume: 34, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Survival Rate; Taxoids	2014
Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Neoplasm Proteins; Osteosarcoma; Precision Medicine; Prognosis; Taxoids; Treatment Outcome	2015
Effect of docetaxel on safety and efficacy of radium-223. The Lancet. Oncology, 2014, Volume: 15, Issue:12 Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids	2014
Antitumor Effect of Docetaxel in Osteosarcoma by the Inhibition of Wnt Signal Channel. Drug research, 2015, Volume: 65, Issue:11 Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Matrix Metalloproteinase 9; Osteosarcoma; Taxoids; Time Factors; Wnt Signaling Pathway	2015
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Auris, nasus, larynx, 2015, Volume: 42, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids	2015
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids	2015
Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2015
Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Fatal Outcome; Humans; Maintenance Chemotherapy; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiography; Taxoids	2015
Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer. Future oncology (London, England), 2015, Volume: 11, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2015
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer? European urology, 2015, Volume: 68, Issue:5 Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2015
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome	2015
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. European urology, 2016, Volume: 69, Issue:6 Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids	2016
Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer. Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Kallikreins; Male; Oligopeptides; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Treatment Outcome; Tumor Burden	2016
New developments in metastatic prostate cancer therapy. The Practitioner, 2015, Volume: 259, Issue:1781 Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Risk Assessment; Taxoids; Therapies, Investigational; United Kingdom	2015
Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. Japanese journal of clinical oncology, 2016, Volume: 46, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Osteosarcoma; Radiotherapy Dosage; Radiotherapy, Adjuvant; Republic of Korea; Retrospective Studies; Taxoids; Treatment Outcome	2016
Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC cancer, 2016, Feb-16, Volume: 16 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Diagnosis, Computer-Assisted; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2016
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC cancer, 2016, Feb-19, Volume: 16 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Diagnosis, Computer-Assisted; Docetaxel; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids	2016
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. BMC urology, 2016, Mar-22, Volume: 16 Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; C-Reactive Protein; Diphosphonates; Docetaxel; Humans; Kallikreins; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Serum Albumin; Survival Rate; Taxoids	2016
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative. Oncotarget, 2016, May-10, Volume: 7, Issue:19 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Interactions; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostatic Neoplasms; Random Allocation; Taxoids; Xenograft Model Antitumor Assays	2016
Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy. Pediatric blood & cancer, 2016, Volume: 63, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Retrospective Studies; Taxoids	2016
Functional roles of CSPG4/NG2 in chondrosarcoma. International journal of experimental pathology, 2016, Volume: 97, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Cartilage, Articular; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chondroitin Sulfate Proteoglycans; Chondrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Peptide Hydrolases; RNA, Small Interfering; Taxoids; Young Adult	2016
Primary osteosarcoma of the uterine corpus: A case report. The journal of obstetrics and gynaecology research, 2016, Volume: 42, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hysterectomy; Lung Neoplasms; Middle Aged; Osteosarcoma; Taxoids; Treatment Outcome; Uterine Neoplasms	2016
Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Multimodal Imaging; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2017
Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone. Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cattle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mice; Molecular Structure; Nanoparticles; RAW 264.7 Cells; Serum Albumin, Bovine; Structure-Activity Relationship; Taxoids	2017
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology, 2016, Volume: 91, Issue:5 Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids	2016
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy. Clinical nuclear medicine, 2017, Volume: 42, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid	2017
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines. Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Chemotherapy, Adjuvant; DNA Repair; Docetaxel; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiopharmaceuticals; Taxoids	2017
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast cancer research and treatment, 2017, Volume: 163, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome	2017
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. BMC cancer, 2017, 03-01, Volume: 17, Issue:1 Topics: Bone Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Oligonucleotide Array Sequence Analysis; Prognosis; Prostatic Neoplasms; Serum Response Factor; Survival Analysis; Taxoids; Transcription Factors; Transcriptional Activation	2017
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-15, Volume: 14, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Disease Progression; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptor, ErbB-3; Solubility; Survival Analysis; Taxoids	2008
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Molecular cancer therapeutics, 2008, Volume: 7, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Mice; Mice, Nude; Osteolysis; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Receptors, Fc; Survival Analysis; Taxoids; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays	2008
[A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2008
Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer research, 2008, Nov-01, Volume: 68, Issue:21 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Bone Neoplasms; Chondrosarcoma, Mesenchymal; Docetaxel; Drug Administration Schedule; Humans; Male; Mice; Middle Aged; Models, Theoretical; Taxoids; Transplantation, Heterologous	2008
Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast cancer research and treatment, 2009, Volume: 118, Issue:2 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Docetaxel; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Taxoids; Xenograft Model Antitumor Assays	2009
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. Journal of cellular biochemistry, 2009, May-01, Volume: 107, Issue:1 Topics: Animals; Antibodies; Antineoplastic Agents; Bone Neoplasms; Chemokine CCL2; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Synergism; Humans; Male; Mice; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays	2009
3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer research, 2009, May-15, Volume: 69, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Therapy, Combination; Female; Humans; Indoles; Inhibitor of Apoptosis Proteins; Luciferases; Male; Mice; Microtubule-Associated Proteins; Neoplasm Metastasis; Plasmids; Prostatic Neoplasms; Survivin; Taxoids	2009
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult	2009
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. British journal of cancer, 2009, Jul-21, Volume: 101, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Neoplasms; Cell Line, Tumor; Dasatinib; Docetaxel; Humans; Male; Mice; Mice, SCID; Osteolysis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Taxoids; Thiazoles; Xenograft Model Antitumor Assays	2009
[A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Taxoids; Toremifene	2009
Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer. The Prostate, 2010, May-01, Volume: 70, Issue:6 Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Male; Mice; Mice, Nude; Oligoribonucleotides, Antisense; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Telomerase; Xenograft Model Antitumor Assays	2010
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Young Adult	2009
A new therapy paradigm for prostate cancer founded on clinical observations. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-15, Volume: 16, Issue:4 Topics: Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Models, Biological; Prostatic Neoplasms; Taxoids	2010
[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Skin Neoplasms; Taxoids; Tomography, X-Ray Computed; Vitamin B 6	2010
Bone metastasis of a breast cancer detected by 3'-deoxy-3'-18F-fluorothymidine PET/CT. Nuklearmedizin. Nuclear medicine, 2009, Volume: 48, Issue:5 Topics: Adult; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Dideoxynucleosides; Docetaxel; Epirubicin; Female; Humans; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2009
Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC cancer, 2010, Jun-13, Volume: 10 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Docetaxel; Erythrocyte Transfusion; Hemoglobins; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Norway; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome	2010
Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas. Cutaneous and ocular toxicology, 2010, Volume: 29, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erythema; Facial Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Nails; Onycholysis; Taxoids	2010
The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. The Prostate, 2010, Sep-01, Volume: 70, Issue:12 Topics: Animals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Disintegrins; Docetaxel; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured	2010
[Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2010
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic oncology, 2012, Volume: 30, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Orchiectomy; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors	2012
MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chinese journal of cancer, 2011, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Mucin-1; Neoplastic Cells, Circulating; Receptors, Progesterone; RNA, Messenger; Taxoids; Thiotepa	2011
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European urology, 2012, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Gossypol; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome	2012
Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids	2011
Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy. The Journal of dermatology, 2011, Volume: 38, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Paget Disease, Extramammary; Skin Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Urinary Bladder Neoplasms	2011
Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. Journal of controlled release : official journal of the Controlled Release Society, 2012, Mar-28, Volume: 158, Issue:3 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Carriers; Humans; Imidazoles; Lactic Acid; Mice; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Zoledronic Acid	2012
Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital. Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:2 Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Osteosarcoma; Retrospective Studies; Taxoids; Treatment Outcome	2012
Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU international, 2012, Volume: 109 Suppl 2 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Congresses as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Palliative Care; Patient-Centered Care; Prognosis; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Taxoids	2012
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Critical reviews in oncology/hematology, 2012, Volume: 83, Issue:3 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids	2012
Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study. BMC research notes, 2012, Mar-22, Volume: 5 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Meta-Analysis as Topic; Middle Aged; Morocco; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids	2012
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report. Clinical genitourinary cancer, 2012, Volume: 10, Issue:3 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome	2012
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Smoking; Taxoids; Tomography, X-Ray Computed	2012
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome	2012
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma; Survival Rate; Taxoids; Young Adult	2012
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. International journal of clinical oncology, 2013, Volume: 18, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Osteosarcoma; Prospective Studies; Taxoids	2013
Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer research, 2012, May-15, Volume: 72, Issue:10 Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Chemokine CCL2; Cyclophosphamide; Docetaxel; Humans; Interleukin-6; Male; Mice; Myeloid Cells; Neoplasm Transplantation; Prostatic Neoplasms; Taxoids	2012
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Transformation, Neoplastic; Disease Progression; Docetaxel; Drug Synergism; Gossypol; Humans; Male; Mice; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Signal Transduction; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays	2012
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Taxoids; Tumor Microenvironment; Xenograft Model Antitumor Assays	2012
Novel and bone-targeted agents for CRPC. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment	2012
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clinical genitourinary cancer, 2013, Volume: 11, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Pain Management; Palliative Care; Proportional Hazards Models; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2013
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Young Adult	2012
Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian journal of andrology, 2013, Volume: 15, Issue:1 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids	2013
[A case of advanced gastric cancer with multiple bone metastases and disseminated intravascular coagulation successfully treated by combination chemotherapy of S-1 plus docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intravascular Coagulation; Docetaxel; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur	2012
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid	2012
Toxic erythema of chemotherapy with periorbital and perioral involvement. Singapore medical journal, 2012, Volume: 53, Issue:11 Topics: Antineoplastic Agents; Axilla; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Erythema; Female; Femur; Gemcitabine; Humans; Hyperpigmentation; Lung Neoplasms; Mouth; Orbit; Osteosarcoma; Taxoids; Treatment Outcome	2012
[A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Taxoids; Young Adult	2012
Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model. The Prostate, 2013, Volume: 73, Issue:9 Topics: Animals; Bone Neoplasms; Cations; Colloids; Disease Models, Animal; Docetaxel; Ferrosoferric Oxide; Hyperthermia, Induced; Liposomes; Magnetics; Male; Prostatic Neoplasms; Random Allocation; Rats; Rats, Inbred F344; Taxoids	2013
Castrate-resistant prostate cancer: postdocetaxel management. Current opinion in urology, 2013, Volume: 23, Issue:3 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Immunotherapy; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome	2013
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer. The Journal of urology, 2002, Volume: 168, Issue:4 Pt 1 Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Humans; Male; Paclitaxel; Platelet Count; Prostatic Neoplasms; Taxoids; Treatment Outcome	2002
[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Paclitaxel; Taxoids	2002
Radiation recall dermatitis from docetaxel. Onkologie, 2002, Volume: 25, Issue:5 Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence; Taxoids	2002
Microangiopathic hemolysis refractory to plasmapheresis responding to docetaxel and cisplatin: a case report. Medical oncology (Northwood, London, England), 2002, Volume: 19, Issue:3 Topics: Adenocarcinoma; Anemia, Hemolytic; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Female; Hemolysis; Humans; Methylprednisolone; Middle Aged; Paclitaxel; Plasmapheresis; Taxoids	2002
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical breast cancer, 2002, Volume: 3, Issue:5 Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin	2002
Cholestatic jaundice and pseudomembranous colitis following combination therapy with doxorubicin and docetaxel. Anti-cancer drugs, 2003, Volume: 14, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Enterocolitis, Pseudomembranous; Female; Humans; Jaundice, Obstructive; Middle Aged; Taxoids	2003
Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients. Japanese journal of clinical oncology, 2004, Volume: 34, Issue:3 Topics: Aged; Alopecia; Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Feasibility Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids	2004
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, May-01, Volume: 22, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids	2004
[Intra-arterial docetaxel chemotherapy with high-dose calcitriol in relapsing metastatic prostate cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Calcitriol; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Quality of Life; Taxoids	2004
[Multidisciplinary treatment for advanced bladder cancer--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Quality of Life; Taxoids; Urinary Bladder Neoplasms	2004
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus. Carcinogenesis, 2004, Volume: 25, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Colony-Forming Units Assay; Disease Progression; DNA Fingerprinting; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Luciferases; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Organ Specificity; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Tumor Cells, Cultured	2004
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease-Free Survival; Docetaxel; Feasibility Studies; Humans; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids	2004
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology, 2005, Volume: 65, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid	2005
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Male; Oropharyngeal Neoplasms; Prostatic Neoplasms; Quality of Life; Taxoids	2005
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast cancer research and treatment, 2005, Volume: 89, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome	2005
Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-01, Volume: 11, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Survival; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblast Growth Factor 2; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Taxoids; Tumor Cells, Cultured	2005
A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:2 Topics: Age Factors; Aged; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2005
[A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Taxoids; Tegafur	2005
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Mitosis; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2005
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2005
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005. Clinical breast cancer, 2005, Volume: 6, Issue:5 Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab	2005
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC cancer, 2006, Jan-17, Volume: 6 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Random Allocation; Taxoids; Tibia; Transplantation, Heterologous; Zoledronic Acid	2006
Breast cancer in pregnancy: are taxanes safe? Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:2 Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Child Development; Docetaxel; Female; Humans; Infant; Male; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Safety; Taxoids	2006
Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer research, 2006, May-01, Volume: 66, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Synergism; Genistein; Glycoproteins; Humans; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Membrane Glycoproteins; Mice; Mice, SCID; NF-kappa B; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays	2006
[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fever; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Prednisolone; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms	2006
[Lung cancer with bone metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8 Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids	2006
[Examination of the safety of docetaxel/cyclophosphamide combination therapy for advanced recurrent breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10 Topics: Adult; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Skin Neoplasms; Stomatitis; Taxoids	2006
[Breast carcinoma and bone chondrosarcoma: a new syndrome?]. Journal de radiologie, 2006, Volume: 87, Issue:11 Pt 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chondrosarcoma; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mammography; Middle Aged; Phenotype; Radiography, Thoracic; Radiotherapy Dosage; Ribs; Syndrome; Taxoids; Tomography, X-Ray Computed	2006
[Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Catheter Ablation; Docetaxel; Fatal Outcome; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Taxoids; Trastuzumab	2006
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene	2007
Docetaxel and beyond. European urology, 2007, Volume: 51, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2007
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer, 2007, Apr-01, Volume: 109, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Bone Marrow Cells; Bone Neoplasms; Caspases; Cell Proliferation; Docetaxel; Drugs, Chinese Herbal; Flow Cytometry; Humans; Immunoenzyme Techniques; Lignans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Tumor Cells, Cultured	2007
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer research, 2007, Apr-15, Volume: 67, Issue:8 Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Cell Line, Tumor; Docetaxel; Lipids; Luciferases; Luminescent Measurements; Magnetic Resonance Imaging; Male; Mice; Mice, SCID; Prostatic Neoplasms; Taxoids; Transfection	2007
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer research, 2007, Apr-15, Volume: 67, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Docetaxel; Drug Synergism; Endothelin A Receptor Antagonists; Humans; Male; Mice; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Taxoids; Xenograft Model Antitumor Assays	2007
Male breast cancer with mandibular metastasis. A case report. Minerva stomatologica, 2007, Volume: 56, Issue:4 Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid	2007
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU international, 2007, Volume: 100, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2007
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2007
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy, 2007, Volume: 53, Issue:6 Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2007
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; British Columbia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2008
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. The Prostate, 2008, Jun-01, Volume: 68, Issue:8 Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Male; Mice; Mice, SCID; Prostatic Neoplasms; Radiography; RANK Ligand; Recombinant Fusion Proteins; Taxoids	2008
The postchemotherapy PSA surge syndrome. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome	2008
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. The Prostate, 2008, Jun-01, Volume: 68, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Everolimus; Humans; Imidazoles; Male; Mice; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Zoledronic Acid	2008
Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Calcitriol; Clinical Trials as Topic; Docetaxel; Drug Synergism; Humans; Hypocalcemia; Male; Prostatic Neoplasms; Taxoids	2008
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International journal of cancer, 1999, Oct-08, Volume: 83, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured	1999
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:10 Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids	1999
Taxane-induced glaucoma. Lancet (London, England), 1999, Oct-02, Volume: 354, Issue:9185 Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Paclitaxel; Recurrence; Taxoids	1999
Mesenteric venous thrombosis attributed to docetaxel. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Mesenteric Vascular Occlusion; Mesenteric Veins; Middle Aged; Osteolysis; Paclitaxel; Sternum; Taxoids; Venous Thrombosis	2000
[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:9 Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Salvage Therapy; Taxoids	2000
Hypertrophic osteoarthropathy associated with docetaxel treatment. Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Docetaxel; Female; Humans; Lung Neoplasms; Mastectomy; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Paclitaxel; Taxoids	2001
[Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5 Topics: Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids	2001
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids	2001
[Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10 Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2001
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:12 Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Tegafur; Uracil	2001
High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone marrow transplantation, 2001, Volume: 28, Issue:11 Topics: Adult; Anthracyclines; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Breast Neoplasms; Cell Separation; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine	2001
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. European journal of cancer care, 2000, Volume: 9, Issue:4 Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids; Treatment Outcome	2000
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2002, Volume: 40, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine	2002